Shots:

• The P-IIb/III (MK-1654-004) trial assessed clesrovimab (105mg, IM) vs PBO to prevent RSV disease in healthy preterm & full-term infants (n=3,632; birth to 1yr.) in their 1st season
• Study showed reduced incidence of RSV-related MALRI requiring ≥1 indicator of LRI by 60.4%, RSV-related hospitalizations by 84.2%, RSV-related LRI hospitalizations by 90.9% & severe MALRI by 91.7%; post hoc analysis depicted a reduced incidence of severe MALRI (requiring ≥2 indicators of LRI) by 88.0% post 5mos.
• Merck also featured P-III (MK-1654-007) study data of clesrovimab vs palivizumab in infants & children, showing 3.6% vs 3% rate of RSV-related MALRI requiring ≥1 indicator of LRI & 1.3% vs 1.5% rate of RSV-related hospitalizations post 5mos.

Ref: Merck | Image: Merck

Related News:- Merck Reports the P-IIb/III Study Data of Clesrovimab (MK-1654) to Prevent RSV Disease in Infants

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com